Covista 10-Q Details Q1 FY2027 Beat: Revenue $511.5M, EPS $1.95, Credit Losses Up
CVSA sits 55% above its 52-week low of $86.97.
Summary
Covista's Q1 FY2027 10-Q confirms the earnings beat — $511.5 million revenue and $1.95 diluted EPS — while flagging a jump in credit-loss provisions to $22.4 million and 19,039 pending Borrower Defense claims.
Key Events · Earnings and Guidance · CVSA
-
Q1 Beat Confirmed in Full Statements
Revenue of $511.5 million rose 10.7% and diluted EPS of $1.95 rose 16.8% from $1.67, with net income of $67.4 million.
-
Segment Mix: Walden and Med/Vet Lead
Walden revenue grew 14.1% to $216.7 million and Medical and Veterinary adjusted operating income jumped 32.7% to $22.3 million; Chamberlain's adjusted operating margin fell to 13.9% from 14.3%.
-
Credit Loss Provision Nearly Doubles
Provision for credit losses rose to $22.4 million from $14.9 million a year ago, lifting the allowance to $70.7 million against $305.6 million of gross accounts and financing receivables.
-
Cash Down on Debt Paydown and Buybacks
Cash and equivalents fell to $222.2 million from $406.3 million after $163.0 million of revolver repayment and $81.0 million of share repurchases; operating cash flow was $114.3 million versus $130.6 million.
Analysis · CVSA · Trade & Services
The 10-Q fills in the numbers behind this morning's earnings release, and they confirm the beat: revenue of $511.5 million (+10.7%) and diluted EPS of $1.95 (+16.8%), with Walden (+14.1% revenue) and the medical/veterinary schools (adjusted operating income +32.7%) doing the heavy lifting while Chamberlain's adjusted operating margin slipped to 13.9% from 14.3%. Less cheerful is the credit book — provision for credit losses jumped to $22.4 million from $14.9 million a year ago and the allowance now stands at $70.7 million — and cash fell to $222.2 million from $406.3 million after $163.0 million of revolver repayment and $81.0 million of buybacks. The filing also quantifies the Borrower Defense exposure for the first time in this cycle: 19,039 claims across the five institutions, with the Department of Education resuming batches in August 2026 and no approvals or recoupment notices received to date.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVSA was trading at $134.66 on NYSE in the Trade & Services sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $86.97 to $152.12. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.